In Vivo Activity of LCB 01-0699 a Prodrug of LCB 01-0648 against Staphylococcus aureus

摘要

>LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of >LCB01-0699, a >LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of >Linezolid. The results of the systemic infection study demonstrated that >LCB01-0699 was more potent than >Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of >LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than >Linezolid. >LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that >LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.